RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Rocket Pharmaceuticals securities during the specified Class Period, alleging misleading statements regarding the safety and clinical trial protocol of RP-A501 [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) and participant deaths in clinical trials [5]. - The firm amended the trial's protocol without informing shareholders, leading to artificially inflated stock prices [5]. Group 2: Investor Participation - Investors who purchased Rocket Pharmaceuticals securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [4].